RecruitingNCT06939985

Cardiometabolic evalUation REgistry of Heart Failure

Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study


Sponsor

Ruijin Hospital

Enrollment

5,000 participants

Start Date

Jan 1, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural/functional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \[EAT\], perivascular adipose tissue \[PVAT\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a registry study collecting data on people with chronic heart failure across different types — including heart failure where the pumping function is reduced, mildly reduced, preserved, or has improved over time. The goal is to evaluate how cardiometabolic factors (like obesity, diabetes, and kidney function) affect heart failure outcomes in real-world patients. **You may be eligible if...** - You are 18 or older - You have been diagnosed with chronic heart failure (any type: reduced, mildly reduced, preserved, or improved ejection fraction) - Your heart failure is symptomatic (NYHA Class II–IV) - You are willing to sign informed consent **You may NOT be eligible if...** - Your estimated survival is less than 1 year - You are pregnant or breastfeeding, or plan to become pregnant within a year - You are unable or unwilling to follow up for visits - You lack the mental or physical ability to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06939985


Related Trials